News EBOS Group Limited

Stocks

EBO

NZEBOE0001S6

Pharmaceuticals

End-of-day quote New Zealand S.E. 2026-10-28			5-day change	1st Jan Change
20.25 ^NZD	-0.05%		+1.25%	-26.68%

10-26	Craigs Investment Partners Adjusts EBOS Group's Price Target to NZ$29.42	MT
10-20	EBOS Group Limited - Shareholder/Analyst Call

All News

Mentions Relevance

10-26	Craigs Investment Partners Adjusts EBOS Group's Price Target to NZ$29.42	MT
10-20	EBOS Group Limited - Shareholder/Analyst Call
09-09	EBOS Group Declares Strike Price for Shares under Dividend Reinvestment Plan	MT
08-19	EBOS Group Limited Declares Final Dividend for the Year 2026, Payable on 18 September 2026	CI
08-18	EBOS Group Limited, 2026 Earnings Call, Aug 19, 2026
08-18	EBOS Group Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-18	Ebos Group Fiscal 2026 Underlying Earnings Down, Revenue Up	MT
08-09	NZX Midday Sector Update: Health Technology Advances, Electronic Technology Declines	MT
06-11	Ebos Group's Proposed Acquisition of Paringa Pet Foods Under Phase One ACCC Review	MT
06-02	Ebos Group Underperforms in Last 12 Months After Contract Loss, Management Shakeup, Jarden Says	MT
05-05	EBOS : Investor Day Presentation	PU
04-30	EBOS Group Limited - Analyst/Investor Day
04-21	EBOS Group Lowers Fiscal 2026 EBITDA Guidance on Higher Energy Costs	MT
03-27	EBOS Group Issues Nearly 2 Million Shares Under Dividend Reinvestment Plan	MT
03-22	EBOS Group Limited(ASX:EBO) dropped from S&P/ASX 200 Index	CI
02-25	EBOS Group Limited acquired an unknown majority stake in MediAdvice Pty Ltd.	CI
02-24	EBOS Group Limited, H1 2026 Earnings Call, Feb 25, 2026
02-24	EBOS : 2026 Interim Report	PU
02-24	EBOS Group Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-24	EBOS Group Posts Lower Fiscal H1 Underlying Earnings, Higher Revenue; Reaffirms Fiscal 2026 Outlook	MT
02-24	EBOS : Interim Shareholders Report 2026	PU
02-24	EBOS Group Limited Declares Ordinary Actual Interim Dividend for the Six Months Ended December 31, 2025, Payable on March 27 2026	CI
02-24	Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect	AQ
01-27	NZX Midday Sector Update: Non-Energy Minerals Soar, Health Technology Struggles	MT
11-06	NZX Biggest Gainers	MT